icad inc. (ICAD): Price and Financial Metrics
Today's Latest Price: $9.78 USD
Nov 27 1:00pm Add ICAD to Watchlist Sign Up
ICAD Stock Summary ICAD's price/sales ratio is 7.85; that's higher than the P/S ratio of 81.8% of US stocks. With a year-over-year growth in debt of -51.63%, Icad Inc's debt growth rate surpasses only 5.87% of about US stocks. In terms of twelve month growth in earnings before interest and taxes, Icad Inc is reporting a growth rate of 46.88%; that's higher than 81.03% of US stocks. If you're looking for stocks that are quantitatively similar to Icad Inc, a group of peers worth examining would be MBII, APDN, NBRV, FLDM, and STXS. Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.
ICAD Price/Volume Stats
icad inc. (ICAD) Company Bio
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.
ICAD Latest News Stream
All News Types
Mgmt Change Product News
Loading, please wait...
Latest ICAD News From Around the Web
Below are the latest news stories about Icad Inc that investors may wish to consider to help them evaluate ICAD as an investment opportunity.
The following slide deck was published by iCAD, Inc. in conjunction with their 2020 Q2 earnings call....
iCAD, Inc. (ICAD) Q2 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Michael Klein - Chairman and Chief Executive Officer Scott Areglado - Chief Financial Officer Stacey Stevens - President Conference Call Participants Dave Turkaly - JMP Securities Per Ostlund -...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
NASHUA, N.H., July 20, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced.
First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman iCAD unveils new.
Read More 'ICAD' Stories Here
ICAD Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8485 seconds.